SCHEMBL20600552

SCHEMBL20600552

OB(O)c1ccc2ncccc2c1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.52
MAPT P10636 2/20 0.52
CYP3A4 P08684 2/20 0.43
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
LMNA P02545 2/20 0.42
HSP90AA1 P07900 2/20 0.42
HSP90AB1 P08238 1/20 0.42
HTT P42858 1/20 0.42
BLM P54132 1/20 0.42
HIF1A Q16665 1/20 0.42
ERN1 O75460 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.38
CYP1A2 P05177 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
NPC1 O15118 1/20 0.37
IDO1 P14902 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MPI P34949 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29955571 0.81 MAPT (0.56) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL29951265 0.76 KDM4E (0.47) KDM4EMAPTERN1
SCHEMBL25200941 0.76 MAPT (0.48) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL25203799 0.76 MAPT (0.48) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL29956251 0.76 MAPT (0.52) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL14242728 0.76 KDM4E (0.58) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL20346 0.76 MAPT (0.52) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL12121729 0.76 MAPT (0.58) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL4054902 0.75 KDM4E (0.62) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL30387307 0.75 KDM4E (0.62) KDM4EMAPTCYP3A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP disclosed
CN-110809577-A Modulators of adenosine A2A receptor 雷沃医疗有限公司 2020-02-18 CN disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR ADORA2A, ADORA1, ADORA3 KDM4E 4607/4885MAPT 1802/4885CYP3A4 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.